PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma to Present at the 27th Annual Piper Jaffray Healthcare Conference
PDL BioPharma Announces Developments Related to LENSAR Debt Investment
PDL BioPharma to Present at the Jefferies Autumn 2015 Global Healthcare Conference
PDL BioPharma Provides Additional Information Regarding Acquired Diabetes Royalty Rights
PDL BioPharma Announces Third Quarter 2015 Financial Results